Caprelsa
(vandetanib)ApprovedSmall molecule
Vandetanib is used to treat certain types of thyroid cancer that have spread or cannot be removed by surgery. It works by slowing or stopping the growth of cancer cells.[2] Caprelsa is currently approved and in use across 16 indications[4].[1]
Caprelsa is one of 419 small molecule programs targeting Breast Cancer. It is currently in Approved.
16
Indications
63
Total Trials
3
Active Trials
418
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 16 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Caprelsa
GGenzyme, a Sanofi Company
Approved
Lexiscan
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thyroid Cancer10 trials
Show 7 more trials
Breast Cancer6 trials
Show 3 more trials
Head and Neck Cancer2 trials
Colorectal Cancer2 trials
37 more indications
Tics2 trials
Glioma2 trials
Prostate Cancer2 trials
Patients With Advanced Solid Tumors2 trials
Efficacy1 trial
Radiation Therapy1 trial
Gastroesophageal Junction1 trial
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
Terminated·—·Phase 1·NCT00732745·9 enrolled
Metastatic Colorectal Cancer1 trial
Hepatocellular Carcinoma1 trial
Malignant Glioma1 trial
Gastrointestinal Stromal Tumor1 trial
Lymphoma1 trial
Relapsed or Refractory1 trial
Midazolam1 trial
Liposomal Doxorubicin1 trial
Urinary Tract Cancer1 trial
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Completed·—·Phase 2·NCT01191892·82 enrolled
Randomized1 trial
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Completed·—·Phase 2·NCT00880334·149 enrolled
Malignant Mesothelioma1 trial
Fallopian Tube Cancer1 trial
Intestinal Cancer1 trial
Primary Peritoneal Cancer1 trial
Metformin1 trial
Treatment1 trial
Thyroid Carcinoma1 trial
Gastroesophageal Junction Cancer1 trial
Paraganglioma1 trial
Metastatic NSCLC1 trial
Lung Carcinoma1 trial
Non-Small Cell Lung Cancer1 trial
Papillary Renal Cell Carcinoma1 trial
Advanced Malignant Neoplasm1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Apr 6, 2011
CAPRELSA
NDA NDA022405
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Caprelsa drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for vandetanib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Ephrin Receptor Inhibitor; Tyrosine-Protein Kinase BRK Inhibitor; Tyrosine-Protein Kinase Receptor RET Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor; Epidermal Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase SRC Inhibitor; Tyrosine-Protein Kinase TIE-2 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- GGenzyme, a Sanofi Company
Patent Landscape[6]
Patent Cliff
Aug 8, 2028
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8067427Aug 8, 2028